{"filings":[{"id":887998,"accession_number":"0001213900-26-065788","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2026-06-05T20:01:14+00:00","items":["5.02"],"status":"ready","headline":"CFO Lisa Locklear to step down July 10; controller Marie Washburn expected as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Lisa Locklear resigns effective July 10, 2026; no disagreement cited.","Controller Marie Washburn anticipated to be elevated to CFO upon Locklear's departure.","Locklear resigning to pursue board opportunities and personal interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68361,"accession_number":"0001213900-26-055806","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2026-05-13T20:14:12+00:00","items":["2.02","9.01"],"status":"ready","headline":"Longeveron reports Q1 net loss of $4.7M; cash $15.8M; HLHS trial data expected August 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.4M, net loss $4.7M vs $5.0M prior year; cash $15.8M at March 31, 2026.","Phase 2b ELPIS II trial in HLHS on track for top-line results in August 2026.","Closed initial $15M of a $30M private placement led by Coastlands Capital and Janus Henderson.","Appointed Stephen H. Willard as CEO in February 2026; cash runway extends into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":398000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94985,"accession_number":"0001213900-26-053902","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Longeveron FDA Type C meeting: ELPIS II trial no longer deemed pivotal; top-line data due Aug 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA stated RVEF is not an appropriate primary endpoint; no new endpoint can be agreed while trial blinded due to NIH interim analysis.","ELPIS II is no longer referred to as pivotal by FDA, reversing prior 2024 discussion.","FDA willing to meet after trial completion; objective measures (mortality, transplant, MACE) could support efficacy.","Company will submit a Sponsor Statistical Analysis Plan with composite primary endpoint for FDA review.","Top-line Phase 2b results for laromestrocel in HLHS still expected in August 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94984,"accession_number":"0001213900-26-042565","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Longeveron restores executive pay cuts, grants CEO 500k RSUs and other execs 250k RSUs after financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company repaid executives and board the full difference between original and reduced salary/fees for period starting Feb 16, 2026, following financing close on March 12, 2026.","Compensation Committee approved RSU grants: 500,000 to CEO and 250,000 to each other executive (excluding Executive Chairman), to be granted May 1, 2026.","RSUs vest quarterly over three years commencing July 1, 2026, under Longeveron's Third Amended and Restated 2021 Incentive Award Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107749,"accession_number":"0001213900-26-034045","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq grants Longeveron 180-day extension to meet $1.00 bid price rule, now due Sept 21, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Extension follows prior non-compliance notice from Sept 22, 2025; original cure deadline was March 23, 2026.","Company must achieve closing bid price of $1.00 or more for 10 consecutive days before Sept 21, 2026.","LGVN may effect a reverse stock split to regain compliance; no assurance of success.","Listing remains active on Nasdaq Capital Market during extension period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107748,"accession_number":"0001213900-26-033501","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Longeveron cancels special meeting, defers reverse stock split vote to annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting of stockholders scheduled for 2026 was cancelled on March 23, 2026.","Reverse stock split proposal will instead be presented at the next annual meeting if deemed necessary.","No specific date provided for the next annual meeting or further details on the split ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107747,"accession_number":"0001213900-26-026930","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01","5.03","3.02","8.01","9.01"],"status":"ready","headline":"Longeveron raises ~$15.9M in private placement with potential additional $15M tied to HLHS milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial gross proceeds of ~$15.9M from sale of 6,013,384 common shares at $0.52 and 11,873 Series A Preferred shares convertible at $0.52.","Second closing of ~$15M contingent on Phase 2b HLHS statistical significance and VWAP ≥ $1.85 on volume ≥25M shares.","Series A Preferred Stock non-voting, convertible to common with 4.99% ownership limitation (holder can increase to 9.99%).","Cash runway extended into Q4 2026, past anticipated Phase 2b ELPIS II topline data in Q3 2026.","Placement agent warrants for 2,019,231 shares at $0.65 (125% of share price), exercisable for 5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107746,"accession_number":"0001213900-26-024839","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Longeveron director Richard Kender resigns; audit committee loses financial expert","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Kender resigned from Board and Audit Committee effective March 3, 2026, due to becoming Executive Chairman and Interim CEO of Seres Therapeutics.","Board appointed Dr. Roger Hajjar to Audit Committee on March 4, but no member currently qualifies as audit committee financial expert.","Company plans to appoint or submit for election a qualified director by next annual meeting or within 180-day cure period.","Kender's resignation not due to any disagreement with the Company's operations, policies, or management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107745,"accession_number":"0001213900-26-016519","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Longeveron appoints Stephen Willard as CEO; Powell resigns; 50% salary deferral enacted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen H. Willard appointed permanent CEO effective Feb 11, 2026; succeeds interim CEO Than Powell who remains in BD role.","Willard receives base salary $500K/yr, deferred to $250K during temporary 50% deferral period for CEO and Executive Chairman.","Initial equity grant: 200K shares, 200K RSUs, 200K stock option; all vest quarterly over four years.","Company implements cost reductions: 50% salary deferral for CEO/Exec Chairman, furloughs, reduced board fees; 50K RSUs to each exec.","Pivotal Phase 2b HLHS trial top-line results expected Q3 2026; FDA guidance that success could support BLA filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124119,"accession_number":"0001213900-25-108533","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Longeveron board directors resign effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Khoso Baluch and Neha Motwani resigned from the Board on Nov 7, 2025.","Neither cited any disagreement with Company operations, policies, or management.","No replacements have been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124118,"accession_number":"0001213900-25-106117","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Longeveron Q3 net loss $17.3M; cash runs late Q1 2026; BLA for HLHS delayed to 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss increased 45% to $17.3M for nine months ended Sept 30, 2025 vs $11.9M in prior year.","Revenue fell 53% to $0.8M; cash and equivalents $9.2M, funding expected only into late Q1 2026.","Top-line results from pivotal HLHS Phase 2b trial ELPIS II expected Q3 2026, but BLA submission now anticipated in 2027.","Completed public offering in Aug 2025 raising ~$5.0M; ATM facility of up to $10.7M available.","Leadership: Than Powell appointed Interim CEO; Dr. Joshua Hare named Executive Chairman; Dr. George Paletta elected to board."],"consensus_eps_estimate":-0.2601,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":834000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124117,"accession_number":"0001213900-25-094710","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Longeveron appoints Dr. George Paletta to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. George Paletta, orthopedic surgeon and St. Louis Cardinals head team doctor, elected to Longeveron Board effective Oct 1, 2025.","Paletta has experience developing ambulatory surgical centers (ASCs) with deal values totaling almost $1 billion.","Paletta holds multiple patents in orthopedic and cardiovascular fields and has been early-stage investor in startups.","Longeveron's pivotal HLHS trial fully enrolled; data anticipated in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140786,"accession_number":"0001213900-25-092316","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Longeveron receives Nasdaq minimum bid price deficiency notice; 180-day cure until March 23, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Longeveron on Sept 22, 2025 that bid price closed below $1.00 for 30 consecutive days.","Company has 180 calendar days (until March 23, 2026) to regain compliance by closing at $1.00+ for 10+ consecutive days.","If bid price falls to $0.10 or less for ten consecutive days before compliance date, immediate suspension/delisting risk.","Company could qualify for an additional 180-day period if it meets other initial listing standards except bid price.","Longeveron will monitor bid price and assess options but cannot assure regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140785,"accession_number":"0001213900-25-089595","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Longeveron enters $10.7M ATM equity offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $10.7M of Class A common stock may be sold at market prices through agent Wainwright.","Commission 3.0% of gross proceeds; company reimburses up to $100k legal fees plus periodic diligence fees.","Net proceeds to fund clinical development of laromestrocel for HLHS, Alzheimer's, and pediatric DCM.","No minimum sales obligation; company or Wainwright may suspend the offering at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140784,"accession_number":"0001213900-25-084112","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO Wa'el Hashad steps down; Than Powell interim CEO; Joshua Hare Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wa'el Hashad resigned as CEO and board member effective August 27, 2025 to pursue other opportunities.","Than Powell, former Chief Business Officer, appointed interim CEO effective September 4, 2025; base salary $500,000 with target bonus.","Founder and CSO Dr. Joshua Hare appointed Executive Chairman; board plans national search for permanent CEO.","Powell has 25+ years pharma/biotech leadership at GSK, Eli Lilly, Surescripts, and Epulate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140783,"accession_number":"0001213900-25-075679","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Longeveron Q2 2025 net loss $10M; HLHS trial fully enrolled, BLA filing targeted late 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for H1 2025 $0.7M (-31% YoY); net loss $10.0M vs $7.5M in H1 2024.","ELPIS II Phase 2b trial for HLHS fully enrolled (40 patients); top-line results expected Q3 2026.","BLA submission for HLHS anticipated in late 2026 contingent on positive trial results.","FDA approved IND for pediatric dilated cardiomyopathy; Phase 2 trial expected H1 2026.","Cash $10.3M as of June 30; with $5M public offering, runway into Q1 2026; seeks additional financing."],"consensus_eps_estimate":-0.3596,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":697000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140782,"accession_number":"0001213900-25-074318","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Longeveron closes $5.0M public offering (up to $17.5M with warrants) for laromestrocel development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $5.0M upfront from offering of ~5.88M shares/pre-funded warrants and 14.7M short-term warrants at $0.85 combined price.","Potential additional $12.5M if short-term warrants (exercisable at $0.85, 24-month term) are fully cash-exercised.","Proceeds to fund clinical/regulatory development of laromestrocel for HLHS, Alzheimer's, pediatric DCM, and BLA readiness.","Placement agent H.C. Wainwright received 7% cash fee plus warrants at $1.0625; board members and insiders participated.","Company subject to 60-day equity issuance lock-up and one-year variable rate transaction ban."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140781,"accession_number":"0001213900-25-062337","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Longeveron receives FDA clearance for Phase 2 trial of laromestrocel in pediatric dilated cardiomyopathy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved IND for a Phase 2 pivotal registration study of laromestrocel for pediatric DCM.","Trial initiation anticipated in first half of 2026.","Nearly 40% of children with DCM require heart transplant or die within 2 years of diagnosis.","Allogeneic mesenchymal stem cell therapy may address anti-inflammatory and pro-vascular mechanisms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158521,"accession_number":"0001213900-25-054755","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Longeveron annual meeting: Rock Soffer elected, plan amendment approved, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rock Soffer re-elected as Class I director with 8,721,836 votes for and 356,027 withheld.","Shareholders approved amendment to 2021 Incentive Award Plan with 8,626,417 for, 425,061 against.","Ratification of CBIZ CPAs as independent auditor for FY2025 passed with 13,967,643 for, 182,971 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158520,"accession_number":"0001213900-25-041066","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Longeveron Q1 net loss $5.0M; HLHS trial 95% enrolled, BLA on track for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net loss $5.0M (up 23% YoY) on revenue $0.4M (down 30%); cash $14.3M, funding late into Q3 2025.","HLHS pivotal trial ELPIS II ~95% enrolled, completion Q2 2025; BLA submission for full traditional approval anticipated in 2026.","CLEAR MIND Alzheimer's Phase 2a results published in Nature Medicine; FDA agreed on pivotal Phase 2/3 trial design for BLA.","Company plans to seek additional financing and partnerships for BLA readiness and Alzheimer's program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":381000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158519,"accession_number":"0001213900-25-037822","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Longeveron Comp Committee approves ongoing Cash-to-Equity Program with Black-Scholes multiplier","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Program allows executives and directors to elect RSUs or stock options in lieu of up to 80% of quarterly cash compensation.","Equity granted at 125%-200% of forgone cash compensation, fully vested upon grant.","Stock options adjusted by an annually reset Black-Scholes multiplier.","Program converted from emergency authorization (May 2024) to ongoing compensatory arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176916,"accession_number":"0001213900-25-024114","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Longeveron auditor changes: Marcum resigns, CBIZ engaged after acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as Longeveron's auditor on March 13, 2025; Audit Committee approved.","CBIZ (acquired Marcum's attest practice) appointed as new independent auditor for FY2025.","No disagreements or reportable events during FY2024, FY2023, and interim through March 13, 2025.","Prior audit reports for FY2024 and FY2023 included going concern explanatory paragraph but were unqualified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176915,"accession_number":"0001213900-25-018776","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Longeveron FY2024 revenue up 237% to $2.4M; net loss narrows 25% to $16.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $2.4M (FY2023: $0.7M) driven by Bahamas Registry Trial and new manufacturing contract.","Net loss $16.0M vs $21.4M in 2023; cash & equivalents $19.2M, runway into Q4 2025.","Pivotal ELPIS II HLHS trial >90% enrolled; enrollment expected to complete Q2 2025.","BLA submission for Lomecel-B (laromestrocel) in HLHS anticipated in 2026 if trial successful.","FDA meeting for mild Alzheimer’s disease pathway expected late Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":2392000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176914,"accession_number":"0001213900-25-008413","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Neil Hare resigns from Longeveron board effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neil Hare resigned from the Board of Directors effective January 27, 2025.","Resignation due to accepting a new professional role that precludes board service.","No disagreement with the Company's operations, policies, or management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193720,"accession_number":"0001213900-24-096799","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Longeveron reports Q3 2024 revenue up 177% YoY to $1.8M; HLHS trial enrollment >80%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for nine months ended Sept 30, 2024: $1.8M, up 177% YoY from $0.6M.","Net loss narrowed to $11.9M for nine months 2024 from $15.3M in 2023, a 23% improvement.","Cash and equivalents $22.8M; expects to fund operations through Q4 2025.","Phase 2b HLHS trial ELPIS II >80% enrolled; FDA confirmed pivotal trial acceptable for BLA if positive.","Phase 2a Alzheimer's data (CLEAR MIND) presented at AAIC and CTAD24."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":1789000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210030,"accession_number":"0001213900-24-069029","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Longeveron reports H1 2024 net loss down 27%; Lomecel-B gets RMAT/Fast Track for Alzheimer's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["H1 2024 net loss $7.5M (down 27% YoY from $10.3M); revenue $1.0M (up 105% YoY from $0.5M).","Cash $12.4M at June 30; July capital raises gross $15.3M (Registered Direct $9.0M, warrant exercises $6.3M); runway through Q4 2025.","FDA granted RMAT and Fast Track for Lomecel-B in mild Alzheimer's after positive Phase 2a CLEAR MIND data at AAIC.","Phase 2b HLHS trial (ELPIS II) at 70% enrollment; targeting completion by end of 2024.","Launched CDMO business; expects $4-5M annual revenue once fully operational."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":1016000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210029,"accession_number":"0001213900-24-062766","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Longeveron raises $9.0M via registered direct offering of 2.24M shares at $4.025; warrants at $3.90","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $9.0M from sale of 2,236,026 shares and concurrent private placement of warrants for 2,236,026 shares.","Warrants exercisable immediately at $3.90 per share for 24 months; placement agent fees of 7% plus warrants at $5.0313.","Net proceeds to fund Lomecel-B clinical programs for HLHS and Alzheimer's disease, regulatory approvals, and working capital.","Closing expected on July 19, 2024; H.C. Wainwright acted as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210028,"accession_number":"0001213900-24-061942","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Longeveron receives FDA Fast Track designation for Lomecel-B in mild Alzheimer's","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track designation granted for Lomecel-B (allogeneic cell therapy) to treat mild Alzheimer’s disease.","Second FDA special designation for Lomecel-B in Alzheimer's, following RMAT designation on July 9, 2024.","Fast Track enables Priority Review (6-month review) and rolling submission; fifth overall special designation.","Phase 2a CLEAR MIND data showed overall slowing/prevention of disease worsening versus placebo.","Full results to be presented at AAIC 2024 (July 28–Aug 1) in Featured Research Session and poster."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210027,"accession_number":"0001213900-24-060281","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Longeveron receives FDA RMAT designation for Lomecel-B in mild Alzheimer's disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for Lomecel-B for mild Alzheimer's disease.","Lomecel-B is the first cellular therapeutic candidate to receive RMAT designation for Alzheimer's disease.","CLEAR MIND Phase 2a trial met primary safety and secondary efficacy endpoints; full results at AAIC on July 28, 2024.","This is the fourth special FDA designation for Lomecel-B; HLHS program holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations.","RMAT designation enables intensive FDA guidance and potential expedited review and accelerated approval pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210026,"accession_number":"0001213900-24-059046","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Longeveron annual meeting: all proposals approved by stockholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected four directors: Joshua M. Hare, Ursula Ungaro, Roger Hajjar, Neha Motwani to three-year terms.","Amendment to 2021 Incentive Award Plan approved with 7.27M votes for, increasing authorized share reserve.","Ratification of Marcum LLP as independent auditor for fiscal 2024 passed with 9.19M votes for.","Broker non-votes present on director election and plan amendment; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228246,"accession_number":"0001213900-24-053828","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Longeveron raises $4.4M from warrant exercise, issues new warrants to fund Lomecel-B development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.4M from exercise of 1,697,891 existing warrants at $2.35/share.","Issued new unregistered warrants to purchase up to 3,395,782 shares at $2.50, 24-month term.","Proceeds for Lomecel-B development (HLHS, Alzheimer's) and general corporate purposes.","H.C. Wainwright acted as exclusive placement agent; fees include 7% cash fee and warrants.","Closing occurred June 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228245,"accession_number":"0001213900-24-041753","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["3.01","5.02","9.01"],"status":"ready","headline":"Longeveron board resignations, appointment of Kender, and Nasdaq compliance cure period","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Pfeffer and Cathy Ross resigned from the Board effective May 6 and May 8, 2024, respectively.","Richard Kender (former Merck SVP) appointed to Board and Audit Committee; receives 16,000 RSUs.","Roger Hajjar and Neha Motwani nominated for election; existing directors Hare and Ungaro also nominated.","Resignations caused non-compliance with Nasdaq majority independent board and audit committee rules.","Company has until November 2, 2024 to regain compliance; intends to appoint additional independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228244,"accession_number":"0001213900-24-034129","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Longeveron raises $6.2M from warrant exercise, total $11.4M; regains Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$6.2M from exercise of 2,399,744 existing warrants at $2.35/share; combined with prior public offering totals ~$11.4M.","Issued new unregistered warrants to purchase up to 4,799,488 shares (Series C: 5-year term, Series D: 24-month term, both at $2.35 exercise price).","Intends to use net proceeds for clinical/regulatory development of Lomecel-B for HLHS, Alzheimer's, and general corporate purposes.","Regained compliance with Nasdaq minimum bid price requirement after closing price >=$1.00 for 13 consecutive business days through April 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228243,"accession_number":"0001213900-24-032239","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Longeveron closes $5.2M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5.2M from 2,234,043 units at $2.35/unit (share + warrant).","Insiders (board members) participated for ~$700k.","Existing warrants amended: exercise price reduced from $16.50 to $2.35; expiration extended.","Net proceeds for Lomecel-B clinical trials in HLHS and Alzheimer's.","H.C. Wainwright placement agent; 7% cash fee plus placement agent warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246990,"accession_number":"0001213900-24-024003","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Longeveron announces 1-for-10 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Outstanding Class A shares reduced from ~10.3M to ~1.03M; Class B from ~14.8M to ~1.48M.","New CUSIP 54303L203; stock trades on Nasdaq as LGVN starting March 27 on split-adjusted basis.","No fractional shares; all fractional interests rounded up to nearest whole share.","Reverse split intended to increase share price to regain Nasdaq minimum bid compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246989,"accession_number":"0001213900-24-020524","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Longeveron receives Nasdaq minimum bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Longeveron on March 4, 2024, that Class A common stock failed to meet $1.00 minimum bid price for 30 consecutive days.","Company has 180 calendar days until August 31, 2024, to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not compliant by August 31, may get additional 180 days if it meets all other initial listing standards except bid price.","Stockholders authorized reverse stock split on February 21, 2024; Board has not yet determined a specific ratio.","If stock closes at $0.10 or less for 10 consecutive trading days before compliance date, Nasdaq can immediately suspend and delist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246988,"accession_number":"0001213900-24-016121","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Longeveron shareholders approve reverse stock split (1:5 to 1:15) at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal approved with 58.8M shares for, 343k against, 187k abstain; no broker non-votes.","Board authorized to set exact ratio between 1:5 and 1:15 without further shareholder approval.","Adjournment proposal also approved with 58.8M for, 318k against, 198k abstain.","Special meeting held February 21, 2024; results filed February 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264406,"accession_number":"0001213900-23-099229","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve issuance of up to 5.0M shares upon warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Dec 26, 2023; proposal to issue up to 5,018,183 shares upon exercise of Purchaser and Placement Agent Warrants approved.","Proposal 1: 73,244,407 for, 106,707 against, 8,413 abstain; Proposal 2 (adjournment): 73,258,560 for, 94,963 against, 6,003 abstain.","Warrants issued in October 2023 registered offering; exercise would exceed 20% of outstanding common stock pre-offering.","Approval removes condition for warrant exercises, enabling potential dilution for existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264405,"accession_number":"0001213900-23-097862","cik":1721484,"company_name":"Longeveron Inc.","ticker":"LGVN","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Longeveron announces $2.36M registered direct offering and warrant private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,355,301 shares at $1.745/share; warrants to purchase 1,355,301 shares at $1.62/share with 5.5-year term.","Gross proceeds of $2.36M before fees; net proceeds for working capital and general corporate purposes.","Closing expected December 22, 2023; H.C. Wainwright acting as exclusive placement agent.","Warrants issued in concurrent private placement, unregistered; resale registration to be filed within 45 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25358555.421373755,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}